Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5034)
All Articles published online
|
Publishing Process of This Article
|
Apr 7, 2014 (publication date) through Apr 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Thomas D, Gazouli M, Karantanos T, Rigoglou S, Karamanolis G, Bramis K, Zografos G, Theodoropoulos GE. Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn’s disease. World J Gastroenterol 2014; 20(13): 3609-3614 [PMID: 24707144 DOI: 10.3748/wjg.v20.i13.3609] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i13/3609.htm |
| Number | Citing Articles |
| 1 |
Rika Nishikawa, Hiroshi Nagai, Toshinori Bito, Tetsuya Ikeda, Tatsuya Horikawa, Atsuko Adachi, Tsukasa Matsubara, Chikako Nishigori. Genetic prediction of the effectiveness of biologics for psoriasis treatment. The Journal of Dermatology 2016; 43(11): 1273 doi: 10.1111/1346-8138.13412
|
| 2 |
Nikolaos-Panagiotis Andreou, Evangelia Legaki, Nikolas Dovrolis, Nikola Boyanov, Konstantinos Georgiou, Kalliopi Gkouskou, Maria Gazouli. B-cell activating factor (BAFF) expression is associated with Crohn's disease and can serve as a potential prognostic indicator of disease response to Infliximab treatment. Digestive and Liver Disease 2021; 53(5): 574 doi: 10.1016/j.dld.2020.11.030
|
| 3 |
Konstantinos Papamichael, Ann Gils, Paul Rutgeerts, Barrett G. Levesque, Séverine Vermeire, William J. Sandborn, Niels Vande Casteele. Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD. Inflammatory Bowel Diseases 2015; 21(1): 182 doi: 10.1097/MIB.0000000000000202
|
| 4 |
Bianca JC van den Bosch, Marieke JH Coenen. Pharmacogenetics of inflammatory bowel disease. Pharmacogenomics 2021; 22(1): 55 doi: 10.2217/pgs-2020-0095
|
| 5 |
Ron Nudel, David M. Hougaard, Thomas Werge, Michael E. Benros. Genetic and epidemiological analyses of infection load and its relationship with psychiatric disorders. Epidemiology and Infection 2023; 151 doi: 10.1017/S0950268823000687
|
| 6 |
Javier Plaza, Alejandro Mínguez, Guillermo Bastida, Remedios Marqués, Pilar Nos, Jose Luis Poveda, Inés Moret-Tatay. Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review. International Journal of Molecular Sciences 2024; 25(7): 3717 doi: 10.3390/ijms25073717
|
| 7 |
Uri Kopylov, Ernest Seidman. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Therapeutic Advances in Gastroenterology 2016; 9(4): 513 doi: 10.1177/1756283X16638833
|
| 8 |
Ming-Hsi Wang, Michael F. Picco. Crohn's Disease. Gastroenterology Clinics of North America 2017; 46(3): 449 doi: 10.1016/j.gtc.2017.05.002
|
| 9 |
Bochao D. Lin, Gonneke Willemsen, Iryna O. Fedko, Rick Jansen, Brenda Penninx, E. de Geus, C. Kluft, JoukeJan Hottenga, Dorret I. Boomsma. Heritability and GWAS Studies for Monocyte–Lymphocyte Ratio. Twin Research and Human Genetics 2017; 20(2): 97 doi: 10.1017/thg.2017.3
|
| 10 |
Mitchell R. K. L. Lie, Emma Paulides, C. Janneke van der Woude. Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events. International Journal of Colorectal Disease 2020; 35(8): 1489 doi: 10.1007/s00384-020-03663-2
|
| 11 |
Chia-Chun Tseng, Man Chun Wong, Wei-Ting Liao, Chung-Jen Chen, Su-Chen Lee, Jeng-Hsien Yen, Shun-Jen Chang. Systemic Investigation of Promoter-wide Methylome and Genome Variations in Gout. International Journal of Molecular Sciences 2020; 21(13): 4702 doi: 10.3390/ijms21134702
|
| 12 |
Emmanouela Rapti, Maria Gazouli, Evangelia Legaki, George Karamanolis, Diamantis Thomas, Evangelos Marinos, Ioannis Papaconstantinou. Association of Survivin Promoter Polymorphisms with Inflammatory Bowel Disease and Response to Antitumor Necrosis Factor Therapy. Genetic Testing and Molecular Biomarkers 2015; 19(6): 339 doi: 10.1089/gtmb.2015.0036
|
| 13 |
Gwan Gyu Song, Young Ho Seo, Jae-Hoon Kim, Sung Jae Choi, Jong Dae Ji, Young Ho Lee. Association between TNF-α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis. Pharmacogenomics 2015; 16(12): 1427 doi: 10.2217/pgs.15.90
|
| 14 |
Boris Gole, Uroš Potočnik. Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn’s Disease—A Systematic Review and Gene Ontology Analysis. Cells 2019; 8(6): 515 doi: 10.3390/cells8060515
|
| 15 |
Yusuke Kawamura, Hirofumi Nakaoka, Akiyoshi Nakayama, Yukinori Okada, Ken Yamamoto, Toshihide Higashino, Masayuki Sakiyama, Toru Shimizu, Hiroshi Ooyama, Keiko Ooyama, Mitsuo Nagase, Yuji Hidaka, Yuko Shirahama, Kazuyoshi Hosomichi, Yuichiro Nishida, Ippei Shimoshikiryo, Asahi Hishida, Sakurako Katsuura-Kamano, Seiko Shimizu, Makoto Kawaguchi, Hirokazu Uemura, Rie Ibusuki, Megumi Hara, Mariko Naito, Mikiya Takao, Mayuko Nakajima, Satoko Iwasawa, Hiroshi Nakashima, Keizo Ohnaka, Takahiro Nakamura, Blanka Stiburkova, Tony R Merriman, Masahiro Nakatochi, Sahoko Ichihara, Mitsuhiro Yokota, Tappei Takada, Tatsuya Saitoh, Yoichiro Kamatani, Atsushi Takahashi, Kokichi Arisawa, Toshiro Takezaki, Keitaro Tanaka, Kenji Wakai, Michiaki Kubo, Tatsuo Hosoya, Kimiyoshi Ichida, Ituro Inoue, Nariyoshi Shinomiya, Hirotaka Matsuo. Genome-wide association study revealed novel loci which aggravate
asymptomatic hyperuricaemia into gout. Annals of the Rheumatic Diseases 2019; 78(10): 1430 doi: 10.1136/annrheumdis-2019-215521
|
| 16 |
Lisa M. Sedger, Michael F. McDermott. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future. Cytokine & Growth Factor Reviews 2014; 25(4): 453 doi: 10.1016/j.cytogfr.2014.07.016
|
| 17 |
Javier P Gisbert, María Chaparro. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020; 14(5): 694 doi: 10.1093/ecco-jcc/jjz195
|
| 18 |
T M Linares-Pineda, M Cañadas-Garre, A Sánchez-Pozo, M Á Calleja-Hernández. Pharmacogenetic biomarkers of response in Crohn’s disease. The Pharmacogenomics Journal 2018; 18(1): 1 doi: 10.1038/tpj.2017.27
|
| 19 |
Sophie Vieujean, Edouard Louis. Precision medicine and drug optimization in adult inflammatory bowel disease patients. Therapeutic Advances in Gastroenterology 2023; 16: 175628482311733 doi: 10.1177/17562848231173331
|